By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...
Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
NEW YORK, Dec 10 (Reuters) - Online telehealth company Hims and Hers Health is launching its weight-loss membership and ...
Stacker on MSN
Ozempic face: The cosmetic concerns of rapid weight loss
Northwell Health reports that "Ozempic face" describes the facial changes from rapid weight loss using Ozempic, highlighting ...
Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...
The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...
A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...
The arrival of Wegovy two years ago caused turmoil in health services around the world ...
Mumbai, Delhi and Bengaluru alone account for one-third of GLP-1 sales. Analysts cite affordability, accessibility and ...
Irish Examiner on MSN
Ozempic, Wegovy and Mounjaro: Why Ireland is struggling to fund the new weight-loss drugs
New weight-loss drugs promise transformative benefits, but soaring demand and massive cost projections leave Ireland facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results